Uterine Leiomyosarcoma.

Leiomyosarcoma (LMS) is the most common soft tissue sarcoma in adults and can occur in any part of the body. Uterine leiomyosarcoma (uLMS) is the most common location for LMS, making up 2% to 5% of all uterine malignancies. It is an aggressive tumor that is challenging to treat because of its resistance to standard therapy.

Addressing the Challenges of Aggressive Lymphomas.

Katherine L. Byar, MSN, ANP-BC, BMTCN®, and Matthew Lunning, DO, FACP, covered how to tackle challenges in the treatment of aggressive lymphomas by understanding how to apply emerging data, reviewing optimal therapies and treatment recommendations, and discovering how to manage associated adverse events in this disease state at JADPRO Live 2019.

Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life.

Purpose/objectives: To identify differences in fatigue, other physical symptoms, and psychological symptoms and their relationship to quality of life (QOL) during chemotherapy and as long as one year after.

Design: Longitudinal, descriptive design embedded in a pilot intervention study.

Setting: Midwestern urban oncology clinics and patient homes.

Quality of life 5 or more years post-autologous hematopoietic stem cell transplant.

This cross-sectional study used a mailed survey to evaluate the quality of life (QOL) of individuals at least 5 years post-autologous stem cell transplant and to determine instrument preference. Instruments selected were the Medical Outcomes Study-Short Form (MOS-SF-36) as the generic measure and the City of Hope-Quality of Life-Bone Marrow Transplant (COH-BMT) and the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) as transplant-specific measures. Subjects received the MOS-SF-36 and were randomized to receive (1) COH-BMT, (2) FACT-BMT, or (3) COH-BMT and FACT-BMT.

Educating patients about radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

Objectives: To present the relevant information for the education of patients with B-cell non-Hodgkin's lymphoma (NHL) who are about to undergo radioimmunotherapy (RIT) with yttrium 90 (90Y) ibritumomab tiuxetan.

Data Sources: Published clinical trials of 90Y ibritumomab tiuxetan and secondary literature on radioimmunotherapy and NHL.

Conclusion: RIT is an emerging therapeutic option for patients with B-cell NHL and promises to become more prevalent in clinical use.